PDUFA dates March 2019: FDA calendar and catalysts.
0 PDUFA dates fell in March 2019. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in March 2019
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
March 2019: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| March 5, 2019 | Spravato (esketamine hydrochloride) | JNJ | FDA approval | — | Approved | openFDA Drugs@FDA |
| March 11, 2019 | Trazimera (trastuzumab-qyyp) | PFE | FDA approval | — | Approved | openFDA Drugs@FDA |
| March 12, 2019 | Rocklatan (latanoprost; netarsudil dimesylate) | ALC | FDA approval | — | Approved | openFDA Drugs@FDA |
| March 18, 2019 | Zykadia (ceritinib) | NVS | FDA approval | — | Approved | openFDA Drugs@FDA |
| March 26, 2019 | Mayzent (siponimod) | NVS | FDA approval | — | Approved | openFDA Drugs@FDA |
March 2019: dated readouts
No events in this view.
Questions
What PDUFA dates are in March 2019?
0 PDUFA dates fell in March 2019. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.